New drug trial offers hope for Tough-to-Treat melanoma after immunotherapy fails
NCT ID NCT07445022
Summary
This study is testing an oral drug called tunlametinib in people with advanced melanoma that has a specific genetic change (NRAS mutation) and has stopped responding to standard immunotherapy. The goal is to see if the drug can shrink tumors and is safe for long-term use in a real-world setting. It will enroll about 110 adults who have already tried and failed anti-PD-1/PD-L1 treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA ADVANCED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.